Loading...
A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Ciuleanu, T Tsai, C Tsao, C Milanowski, J Amoroso, D Heo, D S Groen, H Szczesna, A Chung, C Chao, T
Ciuleanu, T
Tsai, C
Tsao, C
Milanowski, J
Amoroso, D
Heo, D S
Groen, H
Szczesna, A
Chung, C
Chao, T
Citations
Altmetric:
Abstract
Molecularly targeted agents for non-small cell lung cancer (NSCLC) can provide similar efficacy to chemotherapy without chemotherapy-associated toxicities. Combining two agents with different modes of action could further increase the efficacy of these therapies. The TASK study evaluated the efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with the anti-angiogenic agent bevacizumab as first-line therapy in unselected, advanced non-squamous NSCLC patients.
Description
Date
2013-11
Publisher
Collections
Keywords
Type
Article
Citation
A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. 2013, 82 (2):276-81 Lung Cancer